Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Q/C TECHNOLOGIES, INC. entered into Engagement Letter with Katalyst Securities LLC valued at 6% of the gross proceeds.
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Katalyst Securities LLC
- Value
- 6% of the gross proceeds
Exact text from the filing
In connection with the Offering, pursuant to an Engagement Letter (the “Engagement Letter”), between the Company and Katalyst Securities LLC (the “Placement Agent”), the Company has agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds from any sale of securities in the Offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Q/C TECHNOLOGIES, INC. entered into Securities Purchase Agreement with certain accredited investors valued at $15 million (effective 2023-02-21).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- $15 million
- Effective
- 2023-02-21
Exact text from the filing
On February 21, 2023, MyMD Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors in a registered direct offering (the “Offering”) (i) an aggregate of 15,000 shares of the Company’s newly-designated Series F Convertible Preferred Stock with a stated value of $1,000 per share, initially convertible into up to 6,651,885 shares of the Company’s common stock, no par value (the “Common Stock”), at a conversion price of $2.255 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 6,651,885 shares of Common Stock (the “Warrants”). The closing of the Offering is expected to occur on February 23, 2023, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds from the Offering are expected to be $15 million.
View on SEC.gov